Drug development pipeline

The framing

The Alzheimer's pipeline is unlikely to be defined by a single successor to anti-amyloid therapy. The biology supports a portfolio of mechanisms operating at different stages of the disease cascade — discussed in our Insight on why the post-amyloid pipeline is a portfolio bet, not a successor.

Tau-directed therapies

Tau pathology correlates more closely with cognitive decline than amyloid burden. Anti-tau monoclonal antibodies, antisense oligonucleotides, and aggregation inhibitors are in mid- and late-stage trials, with patient selection refined by tau PET. A clinically meaningful tau readout would materially expand the disease-modification toolkit.

Metabolic and vascular mechanisms

GLP-1 receptor agonists — best known for type 2 diabetes and weight management — are now in late-stage Alzheimer's trials. Phase 3 readouts on semaglutide are imminent. The interest spans metabolic, inflammatory, and direct neuronal pathways.

Neuroinflammation

Microglia-modulating approaches and broader anti-inflammatory mechanisms are advancing, generally at earlier stages than the tau or anti-amyloid programs. Biomarker validation remains a key open question.

Synaptic and neuronal resilience

Several programs target the maintenance of synaptic function in the face of accumulating pathology. Mechanistically diverse, mostly in earlier development.

Genetic and protein-clearance approaches

Programs targeting APOE biology directly, lysosomal-pathway-modulating agents, and other protein-handling mechanisms are in earlier-stage development. The research thesis here is that addressing the upstream biology may complement amyloid clearance.

What we are watching

The next material readouts — tau program registration trials, the phase 3 GLP-1 results, and several anti-amyloid combination studies — will determine how the next era of treatment is shaped. The most likely future is one in which mechanisms are sequenced and combined, rather than one in which any single mechanism takes the field.